Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial

被引：0
|
作者：
Craig, T. J. [1 ]
Reshef, A. [2 ]
Lumry, W. R. [3 ]
Saguer, I. Martinez [4 ]
Jacobs, J. S. [5 ]
Yang, W. H. [6 ]
Aygoren-Pursun, E. [7 ]
Keith, P. K. [8 ]
Busse, P. [9 ]
Magerl, M. [10 ]
Feuersenger, H. [11 ]
Bica, M. A. [11 ]
Glassman, F. [12 ]
Pragst, I. [11 ]
Levy, D. S. [13 ]
机构：
[1] Penn State Univ, Dept Med & Pediat, Allergy Asthma & Immunol, Hershey, PA USA
[2] Barzilai Univ Hosp, Allergy & Immunol Angioedema Ctr, Ashqelon, Israel
[3] AARA Res Ctr, Dallas, TX USA
[4] HZRM Haemophilia Ctr Rhein Main, Morfelden Walldorf, Germany
[5] Allergy & Asthma Clin Res, Walnut Creek, CA USA
[6] Univ Ottawa, Ottawa Allergy Res Corp, Dept Med, Ottawa, ON, Canada
[7] Klinikum Johann Wolfgang Goethe Univ, Klin Kinder & Jugendmed, Frankfurt, Germany
[8] McMaster Univ, Med Ctr Site, Hamilton, ON, Canada
[9] Mt Sinai, New York, NY USA
[10] Charite Univ Med Berlin, Inst Allergol, Fraunhofer Inst Translat Med & Pharmacol ITMP All, Berlin, Germany
[11] CSL Behring Innovat GmbH, Marburg, Germany
[12] CSL Behring, King Of Prussia, PA USA
[13] Univ Calif Irvine, Div Allergy & Immunol, Irvine, CA USA
来源：
ALLERGOLOGIE | 2023年 / 46卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P8.10
引用
收藏
页码：560 / 561
页数：2
相关论文
共 50 条
  • [1] Garadacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial
    Reshef, A.
    Magerl, M.
    Saguer, I. Martinez
    Bernstein, J. A.
    Farkas, H.
    Yang, W. H.
    Jacobs, J. S.
    Li, P. Hei
    Lumry, W. R.
    Aygoeren-Puersuen, E.
    Ohsawa, I.
    Katelaris, C.
    Longhurst, H.
    Hakl, R.
    Guilarte, M.
    Stroes, E. S. G.
    Feuersenger, H.
    Bica, M. A.
    Jacobs, I.
    Craig, T. J.
    [J]. ALLERGOLOGIE, 2023, 46 (08) : 561 - 562
  • [2] Garadacimab For Hereditary Angioedema Prophylaxis In Adolescents: Efficacy And Safety From The Phase 3 (VANGUARD) Study And Open-Label Extension (Second Interim Analysis)
    Jacobs, Joshua
    Magerl, Markus
    Martinez-Saguer, Inmaculada
    Li, Huamin
    Bernstein, Jonathan
    Hsu, Connie
    Sitz, Karl
    Wieman, Lolis
    Feuer-Senger, Henrike
    Pollen, Maressa
    Reshef, Avner
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB6 - AB6
  • [3] Garadacimab for hereditary angioedema prophylaxis in adolescents: efficacy and safety from the VANGUARD Phase 3 and 3b open-label extension trial (first interim analysis)
    Magerl, M.
    Saguer, I. Martinez
    Jacos, J. S.
    Li, H.
    Bernstein, J. A.
    Hsu, C.
    Sitz, K. V.
    Pragst, I.
    Feuersenger, H.
    Wieman, L.
    Pollen, M.
    Rese, A.
    [J]. ALLERGOLOGIE, 2023, 46 (08) : 562 - 562
  • [4] Integrated Safety And Efficacy Of Garadacimab For Hereditary Angioedema Prophylaxis Across 3 Clinical Trials: Phase 2, Pivotal Phase 3, And Open-Label Extension Studies
    Craig, Timothy
    Anderson, John
    Jacobs, Joshua
    Tachdjian, Raffi
    Farkas, Henriette
    Yang, William
    Ohsawa, Isao
    Pollen, Maressa
    Lawo, John-Philip
    Bica, Alex
    Jacobs, Iris
    Magerl, Markus
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB256 - AB256
  • [5] LONG-TERM SAFETY AND EFFICACY WITH GARADACIMAB FOR HEREDITARY ANGIOEDEMA PROPHYLAXIS IN AN OPEN- LABEL EXTENSION STUDY
    Anderson, J.
    Levy, D.
    Sussman, G.
    Jacobs, J.
    Farkas, H.
    Pollen, M.
    Feuersenger, H.
    Craig, T.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S5 - S5
  • [6] Long-term efficacy and safety of subcutaneous garadacimab for prophylaxis of hereditary angioedema attacks: Results from a multicentre phase 3 study and open-label extension
    Magerl, M.
    Reshef, A.
    Farkas, H.
    Li, H. H.
    Jacobs, J. S.
    Bernstein, J.
    Yang, W.
    Stroes, E. S.
    Ohsawa, I.
    Tachdjian, R.
    Manning, M. E.
    Lumry, W. R.
    Saguer, I. Martinez
    Aygoeren-Puersuen, E.
    Ritchie, B.
    Sussman, G. L.
    Anderson, J.
    Kawahata, K.
    Suzuki, Y.
    Staubach, P.
    Treudler, R.
    Feuersenger, H.
    Jacobs, I.
    Craig, T. J.
    [J]. ALLERGY, 2023, 78 : 115 - 117
  • [7] Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study
    Craig, Timothy J.
    Levy, Donald S.
    Reshef, Avner
    Lumry, William R.
    Martinez-Saguer, Inmaculada
    Jacobs, Joshua S.
    Yang, William H.
    Ritchie, Bruce
    Aygoeren-Puersuen, Emel
    Keith, Paul K.
    Busse, Paula
    Feuersenger, Henrike
    Bica, Mihai Alexandru
    Jacobs, Iris
    Pragst, Ingo
    Magerl, Markus
    [J]. LANCET HAEMATOLOGY, 2024, 11 (06): : e436 - e447
  • [8] A phase 3 open-label extension study of the efficacy and safety of lanadelumab for the prevention of angioedema attacks in patients with hereditary angioedema: trial design
    Riedl, M.
    Bernstein, J. A.
    Craig, T.
    Banerji, A.
    Magerl, M.
    Cicardi, M.
    Longhurst, H. J.
    Shennak, M.
    Yang, W.
    Schranz, J.
    Baptista, J.
    Busse, P.
    [J]. ALLERGY, 2017, 72 : 598 - 599
  • [9] PHASE 2 OPEN-LABEL EXTENSION STUDY WITH DONIDALORSEN TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Bordone, L.
    Riedl, M.
    Newman, K.
    Lui, C.
    Alexander, V.
    Schneider, E.
    Cohn, D.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S33 - S33
  • [10] A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema
    Petersen, Remy S.
    Bordone, Laura
    Riedl, Marc A.
    Tachdjian, Raffi
    Craig, Timothy J.
    Lumry, William R.
    Manning, Michael E.
    Bernstein, Jonathan A.
    Raasch, Jason
    Zuraw, Bruce L.
    Deng, Yiwen
    Newman, Kenneth B.
    Alexander, Veronica J.
    Lui, Cindy
    Schneider, Eugene
    Cohn, Danny M.
    [J]. ALLERGY, 2024, 79 (03) : 724 - 734
12345